液体活检在非小细胞肺癌患者中的临床应用：临床实践现状与最新进展
Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice.
作者信息
Park Shinhee, Lee Jae-Cheol, Choi Chang-Min
机构信息
Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea.
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
出版信息
J Clin Med. 2021 May 21;10(11):2236. doi: 10.3390/jcm10112236.
Recent advances in targeted and immune therapies have enabled tailored treatment strategies for advanced lung cancer. Identifying and understanding the genomic alterations that arise in the course of tumor evolution has become hugely valuable, but tissue biopsies are often insufficient for representing the whole cancer genome due to tumor heterogeneity. A liquid biopsy refers to the isolation and analysis of any tumor-derived material in the blood, and recent studies of this material have mostly focused on cell-free tumor DNA (ctDNA) in plasma. Indeed, liquid biopsy analysis is now expected to expand in utility and scope in clinical practice. In this review, we assess the biology and technical aspects of ctDNA analysis and discuss how it is currently applied in the clinic. Key points: Liquid biopsy is a potentially powerful tool in the era of personalized medicine for guiding targeted therapies in non-small cell lung cancer.
靶向治疗和免疫治疗的最新进展为晚期肺癌带来了量身定制的治疗策略。识别和理解肿瘤进化过程中出现的基因组改变已变得极具价值，但由于肿瘤异质性，组织活检往往不足以代表整个癌症基因组。液体活检是指对血液中任何肿瘤来源物质的分离和分析，最近对这种物质的研究主要集中在血浆中的游离肿瘤DNA（ctDNA）。事实上，液体活检分析目前有望在临床实践中扩大其效用和范围。在本综述中，我们评估了ctDNA分析的生物学和技术方面，并讨论了其目前在临床上的应用方式。要点：在个性化医疗时代，液体活检是指导非小细胞肺癌靶向治疗的潜在有力工具。
Zotero 插件